HIV in the current day
Antiretroviral therapies (ART) and pre-exposure prophylaxis (PrEP) have been revolutionary in the fight against HIV. Despite this, in 2023 roughly 27,000 people were newly diagnosed with HIV in Western Europe. An understanding of the circumstances around contracting HIV is crucial to elimination efforts.
Our aim
The CASCADE study aims to understand the experiences and needs behind the use or disuse of prevention methods, including PrEP, from the people who are most affected. With better research and understanding we hope to impact HIV health strategies to better serve key populations.
The CASCADE study is a multi-centre study funded through grants from ViiV Healthcare UK and Merck Sharp & Dohme Corporation.
Publications
See where insights from the study have been disseminated through academic publication.
Key project information
Dates: January 2022 to December 2027
Status: Current
UCL lead/Principal Investigator: Professor Fiona Burns
Partners: InfCare (Sweden), Southern Alberta (Canada), Aquitaine (France), FHDH (France), PRIMO (France), CoRIS (Spain), AMACS (Greece) and ATHENA (Netherlands)
Participating sites
CASCADE has many participating sites across Western Europe and Canada.
Contact us
For any inqueries, email us at CASCADE@ucl.ac.uk.
